BaseSpace
Correlation Engine 2.0
Import Your Data
QuickView

FAQ

More QuickView FAQs

Back to top
Clear Search sequence regions
(e.g. Pseudomonas infection, Adipose tissue, DNA fingerprint, Phenobarbital, rs6983267, LEP)
Bookmark Forward

QuickView for cyclin-dependent protein serine/threonine kinase inhibitor activity (biogroup)


Body Atlas

Most Correlated Tissues

  1. Vagina
  2. Stomach
  3. Skeletal muscle
  4. Testes
  5. Salivary gland
Explore Body Atlas Results

Disease Atlas

Most Correlated Diseases

  1. Vesicular stomatitis Indiana virus disease
  2. Myocardial ischemia
  3. Perforation of tympanic membrane
  4. Infection due to Mycobacterium tuberculosis
  5. Injury of integument
Explore Disease Atlas Results

Pharmaco Atlas

Most Correlated Compounds

  1. Apitolisib
  2. RPI-1 cpd
  3. ((3Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide)
  4. SB 525334
  5. ompP2 protein, Haemophilus influenzae
Explore Pharmaco Atlas Results

Knockdown Atlas

Most Correlated Gene Perturbations

  1. CASP8AP2
  2. ZBTB16
  3. BAK1
  4. NR5A1
  5. ZCCHC24
Explore Knockdown Atlas Results

Curated Studies

Most Correlated Studies

  1. Oral keratinocytes HOK16B cells treated with cannabidiol before LPS + ATP mediated inflammation
  2. Gene expression from U937T:PLZF-RARa Inducible Cells
  3. L1000 CMAP - Colorectal cancer HT29.311 cells with CRISPR-targeted gene knockouts
  4. HCT116 cells isogenic for p53 expression upon treatment with actinomycin D and nutlin-3
  5. L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
Explore Curated Studies Results

Literature

Most Relevant Literature

  1. Identification of novel molecular markers through transcriptomic analysis in human fetal and adult c…
  2. Melatonin-induced gene expression changes and its preventive effects on adriamycin-induced lipid per…
Explore Literature Results

Clinical Trials

Most Relevant Clinical Trials

  1. A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast Cancer
  2. A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2…
  3. Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Perio…
  4. Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Ho…
Explore Clinical Trials Results
  • Copyright © 2024 Illumina Inc. All rights reserved.